A Double-blind, Randomized, Controlled Trial Comparing the Safety and Efficacy of AMDC-USR With Placebo in Female Subjects With Stress Urinary Incontinence
Latest Information Update: 11 Nov 2024
At a glance
- Drugs Iltamiocel (Primary)
- Indications Urinary incontinence; Urinary-Stress-Incontinence
- Focus Registrational; Therapeutic Use
- Acronyms IND2
- Sponsors Cook MyoSite
- 01 Nov 2024 Primary endpoint (Participants With 50% Reduction in Stress Incontinence Episode Frequency From Baseline to 12 Months Post-treatment; as Assessed by 3 Day Diary) has not been met, according to Results published in the Neurourology and Urodynamics.
- 01 Nov 2024 Results assessing the efficacy and safety of iltamiocel in females with stress urinary incontinence, published in the Neurourology and Urodynamics.
- 13 Sep 2021 Results (n=75) of women with persistent or recurrent stress urinary incontinence following surgery, presented at the 116th Annual Meeting of the American Urological Association